- Home
- CCSI vs PRTA Comparison
CCSI vs PRTA Comparison
Compare CCSI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCSI
- PRTA
- Stock Information
- Founded
- CCSI 2021
- PRTA 2012
- Country
- CCSI United States
- PRTA Ireland
- Employees
- CCSI N/A
- PRTA N/A
- Industry
- CCSI Retail: Computer Software & Peripheral Equipment
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- CCSI Technology
- PRTA Health Care
- Exchange
- CCSI Nasdaq
- PRTA Nasdaq
- Market Cap
- CCSI 450.6M
- PRTA 472.1M
- IPO Year
- CCSI N/A
- PRTA N/A
- Fundamental
- Price
- CCSI $28.49
- PRTA $8.06
- Analyst Decision
- CCSI Hold
- PRTA Buy
- Analyst Count
- CCSI 5
- PRTA 10
- Target Price
- CCSI $27.20
- PRTA $12.29
- AVG Volume (30 Days)
- CCSI 104.0K
- PRTA 869.0K
- Earning Date
- CCSI 11-06-2025
- PRTA 11-11-2025
- Dividend Yield
- CCSI N/A
- PRTA N/A
- EPS Growth
- CCSI N/A
- PRTA N/A
- EPS
- CCSI 4.15
- PRTA N/A
- Revenue
- CCSI $349,595,000.00
- PRTA $10,341,000.00
- Revenue This Year
- CCSI $1.55
- PRTA N/A
- Revenue Next Year
- CCSI $1.10
- PRTA $602.32
- P/E Ratio
- CCSI $6.87
- PRTA N/A
- Revenue Growth
- CCSI N/A
- PRTA N/A
- 52 Week Low
- CCSI $17.84
- PRTA $4.32
- 52 Week High
- CCSI $32.10
- PRTA $22.41
- Technical
- Relative Strength Index (RSI)
- CCSI 67.06
- PRTA 49.02
- Support Level
- CCSI $26.82
- PRTA $8.10
- Resistance Level
- CCSI $28.55
- PRTA $8.50
- Average True Range (ATR)
- CCSI 0.73
- PRTA 0.33
- MACD
- CCSI 0.01
- PRTA -0.10
- Stochastic Oscillator
- CCSI 73.60
- PRTA 3.45
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.